Ovid Therapeutics Inc (OVID) Company Profile & Statistics

Ovid Therapeutics Inc
OVID
(Nasdaq - US)
N/A
3.14
-0.13 (-4.12%)
in:usd•As of: May 17, 2024 15:59 UTC -4
Open
3.28
High
3.28
Low
3.14

About Ovid Therapeutics Inc

CEO

Jeremy M. Levin

Headquarters

441 ninth avenue, 14th floor

new york, ny 10001, united states

Auditor

KPMG LLP

Employees

Share Holders

Website

www.ovidrx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.

Ovid Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	222.75M
Enterprise Value	207.68M
Enterprise Value/EBITDA (ttm)	-3.45
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.00
Price to Sales (ttm)	496.91
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-10691.14%
Profit Margin (ttm)	-11395.78%
Return on Equity (ttm)	-53.62%
Return on Invested Capital (ttm)	-47.07%
Return on Assets (ttm)	-37.76%

Income Statement

Revenue (ttm)	473.70K
Revenue Per Share (ttm)	0.01
Gross Profit (ttm)	473.70K
EBITDA (ttm)³	-60.22M
Net Income Avi to Common (ttm)	-50.68M
Diluted EPS (ttm)	-0.73

Share Statistics

Beta (5Y Monthly)	0.69
52-Week Change	-9.25%
S&P500 52-Week Change	26.33%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	70.94M
Dividend Yield	0.00%
Float ⁴	61.39M
% Held by Insiders	13.30%
% Held by Institutions	72.24%

Balance Sheet

Total Cash (mrq)	90.26M
Total Cash Per Share (mrq)	1.27
Total Debt (mrq)	15.70M
Total Debt/Equity (mrq)	20.05%
Current Ratio (mrq)	10.46%
Quick Ratio (mrq)	9.55%
Book Value Per Share (mrq)	1.11

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.24
Free Cash Flow (ytd)	-16.70M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Ovid Therapeutics Inc

Trade With A Regulated Broker